Skip to content

A Study to Evaluate the Clinical Performance of VeriSee GLC for Screening of Glaucoma Suspect Using Color Fundus Images

A Study to Evaluate the Clinical Performance of VeriSee GLC for Screening of Glaucoma Suspect Using Color Fundus Images

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07550712
Enrollment
773
Registered
2026-04-24
Start date
2024-08-26
Completion date
2024-12-27
Last updated
2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Glaucoma suspect

Brief summary

The goal of this observational study is to evaluate the clinical performance of VeriSee GLC for identifying glaucoma suspects using color fundus images in adult participants. The main questions it aims to answer are: * What are the sensitivity and specificity of VeriSee GLC for detecting glaucoma suspects based on fundus images? * How does the performance of VeriSee GLC compare with the reference standard defined by the majority consensus of three independent evaluators? Researchers will compare the screening results generated by VeriSee GLC with the reference standard to assess its diagnostic performance. This retrospective study will use previously collected fundus images. VeriSee GLC performs automated image analysis to identify glaucomatous signs, including retinal nerve fiber layer (RNFL) defects, vertical cup-to-disc ratio (VCDR) enlargement, and rim-to-disc ratio (RDR) changes. The output is intended to assist healthcare professionals in identifying glaucoma suspects for referral, rather than providing a definitive diagnosis.

Interventions

None listed

Sponsors

Acer Medical Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum

Inclusion criteria

1. The adult color fundus image (aged 20 and above) 2. The requirements of color fundus image * The resolution of image is 1024 × 1024 pixels or higher; * The angle view of image is 45-or 50-degree. * Images captured from eyes with myopia not exceeding -10 diopters. 3. The color fundus image includes the optic disc and RNFL areas, and one of these areas is evaluable, as judged by the healthcare professionals.

Exclusion criteria

1. The color fundus images previously used by VeriSee GLC during the development process and pre-clinical test. 2. A color fundus image of patients with cataracts, acute angle closure glaucoma or those who have undergone retinal laser surgery. 3. The optic disc and RNFL areas in the color fundus images is invisible to determine the disease condition as judged by the healthcare professionals.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and Specificity of the VeriSee GLC for Screening Glaucoma Suspects1 DayThe primary outcome is the sensitivity and specificity of the VeriSee GLC in identifying glaucoma suspects based on color fundus images, compared against the reference standard defined by the majority consensus of three independent evaluators.

Secondary

MeasureTime frameDescription
Positive Predictive Value (PPV), Negative Predictive Value (NPV), and Accuracy of VeriSee GLC for Screening Glaucoma Suspects1 DayEvaluate the PPV, NPV, and overall accuracy of the VeriSee GLC in identifying glaucoma suspects relative to the reference standard.
Accuracy of Detection for 3 Glaucomatous Signs - VCDR and RDR1 DayAssess the accuracy of VeriSee GLC in detecting three glaucomatous signs: * Vertical cup-to-disc ratio (VCDR ≥ 0.7) * Rim-to-disc ratio (RDR ≤ 0.1) * Retinal nerve fiber layer (RNFL) defect
Accuracy of Detection for 3 Glaucomatous Signs - RNFL Defect1 DayAssess the accuracy of VeriSee GLC in detecting three glaucomatous signs: * Vertical cup-to-disc ratio (VCDR ≥ 0.7) * Rim-to-disc ratio (RDR ≤ 0.1) * Retinal nerve fiber layer (RNFL) defect
Dice Coefficient of Disc and Cup Contours1 DayDice coefficient measures the similarity between contours generated by VeriSee GLC and evaluator annotations. The Dice coefficient ranges from 0 (no overlap) to 1 (perfect agreement).

Countries

Taiwan

Participant flow

Recruitment details

\[Not Specified\]

Pre-assignment details

\[Not Specified\]

Baseline characteristics

Characteristic
Age, Continuous60 years
STANDARD_DEVIATION 14.7
Sex: Female, Male
Female
466 Participants
Sex: Female, Male
Male
307 Participants
Spherical Equivalent-2.7 Diopter (D)
STANDARD_DEVIATION 3.1

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 0
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026